香港醫思醫療集團(02138.HK)擬採納共同持股計劃
格隆匯2月25日丨香港醫思醫療集團(02138.HK)公佈,為根據規則向具備專業才能及經驗豐富的合資格參與者提供機會購買公司股權,並進一步使其權益與長期股東保持一致,從而激勵彼等留任集團並鼓勵彼等為集團的未來發展及擴張而努力,為股東創造價值。於2020年2月21日,董事會考慮及批准於滿足批准條件獲達成後採納持股管理人計劃。
倘計劃授權獲批准及悉數動用,則2955.8323萬股新股份將予發行,佔公司現有已發行股本約3%,及佔經擴大後股本約2.91%;此外,根據用以交割授出獎勵股份的關連購買獎勵股份,可向關連賣方購買最多股份數目為可予發行的獎勵股份總數,即約696.5971萬股股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.